Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib trials studies the side effects of daratumumab and ibrutinib and how well they
work in treating patients with symptomatic chronic lymphocytic leukemia. Monoclonal
antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and
spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth. Giving daratumumab and ibrutinib may work better in treating patients with
chronic lymphocytic leukemia.